- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05312970
Varithena Versus Endothermal Ablation of the Great Saphenous Vein (VERITAS) (VERITAS)
March 21, 2024 updated by: Boston Scientific Corporation
A Phase 4 Randomized Trial Comparing Varithena to Endothermal Ablation for the Treatment of the Great Saphenous Vein
The purpose of this study is to observe insights into the benefits of Varithena compared to Endothermal Ablation (ETA) in the treatment of the great saphenous vein.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
To collect comparative evidence on patient reported outcomes of Varithena compared to ETA when used to treat the incompetent great saphenous vein (GSV).
ETA will include either radiofrequency ablation or endovenous laser ablation according to the site's standard practice.
To provide long term (1-year, 2-year, and 3-year) outcomes.
Study Type
Interventional
Enrollment (Estimated)
100
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Timothy Keo
- Phone Number: 425.599.3814
- Email: Timothy.Keo@bsci.com
Study Contact Backup
- Name: Sharon Mensah
- Phone Number: 612.403.7653
- Email: Sharon.Mensah@bsci.com
Study Locations
-
-
Connecticut
-
Darien, Connecticut, United States, 06820
- Recruiting
- Vascular Care Connecticut
-
Contact:
- Paul J Gagne, MD
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20057
- Recruiting
- MedStar Georgetown University Hospital
-
Contact:
- Misaki Kiguchi, MD
-
-
Louisiana
-
Houma, Louisiana, United States, 70360
- Recruiting
- Cardiovascular Institute of the South
-
Contact:
- Craig Walker, MD
-
-
Maine
-
South Portland, Maine, United States, 04106
- Recruiting
- Vein Healthcare Center
-
Contact:
- Cindy Asbjornsen, DO
-
-
New Jersey
-
Englewood, New Jersey, United States, 07631
- Recruiting
- Englewood Hospital and Medical Center
-
Contact:
- Steven Elias, MD
-
-
New York
-
New York, New York, United States, 10032
- Recruiting
- Columbia University Medical Center
-
Contact:
- Danielle R Bajakian, MD
-
Stony Brook, New York, United States, 11794
- Suspended
- Stony Brook University Hospital
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- UT Physicians Cardiothoracic and Vascular Surgery
-
Contact:
- Stuart Harlin, MD
-
-
Washington
-
Bellevue, Washington, United States, 98004
- Recruiting
- Lake Washington Vascular
-
Contact:
- Kathleen Gibson, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age ≥ 18
- Primary GSV incompetence, defined as reflux > 0.5 seconds on Duplex ultrasound in a single limb (Note the contralateral limb can have varicosities or SVI if intervention is not required within 3 months i.e. asymptomatic)
- Failed conservative therapy (compression, diet, exercise, leg elevation)
- CEAP Clinical Condition Classification C2 - C6
- Vein diameter 5-10mm, inclusive
- GSV treatable length > 10cm
- Superficial venous disease manifest by clinical symptoms (rVCSS ≥ 4)
- Able to comprehend and sign an informed consent document and complete written study questionnaires
- Willing and able to return for scheduled follow-up visits (7-days, 3-months, 6-months, 12-months, 24-months, and 36-months post-procedure)
- Willingness to comply with post-treatment compression protocol
Exclusion Criteria:
- Allergy to polidocanol, xylocaine, or epinephrine
- Deep vein thrombosis or pulmonary embolism within 3 months prior to randomization or hypercoagulable disorder
- Post thrombotic deep vein disease above the calf veins
- Pregnancy or lactating (within 30 days of randomization)
- Symptomatic peripheral arterial disease or ankle-brachial pressure index (ABPI) < 0.8
- Previous treatment to targeted incompetent GSV or previous superficial thrombophlebitis in targeted GSV
- Previous venous intervention in affected limb in past 3 months
- Local aneurysmal GSV segments
- Inability to walk unaided
- Inability to wear post-procedure compression bandaging and stockings
- Patients with clinically significant reflux of the small saphenous vein (SSV) or anterior accessory saphenous vein (AASV)
- In the clinical judgement of the investigator, patient who will require ipsilateral deep venous intervention within 3 months following randomized treatment
- In the clinical judgement of the investigator, patient who will require contralateral venous intervention (superficial or deep) within 3 months following randomized treatment
- Patient on therapeutic anticoagulants
- Active malignancy
- Life expectancy < 2 years
- Documented COVID-19 infection currently or within 2 months prior to randomization
- Enrollment in another clinical trial that could confound the endpoint within 3 months prior to screening or within 3 months following enrollment
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Varithena®
Varithena® (polidocanol injectable foam) 1%
|
Varithena® (polidocanol injectable foam) 1%
|
Active Comparator: FDA-approved ETA systems
FDA-approved ETA systems, including Radiofrequency ablation (RFA) systems or Endovenous laser ablation (EVLA) systems.
|
FDA-approved ETA systems, including Radiofrequency ablation (RFA) systems or Endovenous laser ablation (EVLA) systems.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Varicose Veins Symptoms Questionnaire (VVSymQ)
Time Frame: Baseline to 3-month post treatment
|
Mean change in Varicose Veins Symptoms Questionnaire (VVSymQ) between baseline and 3-month post treatment
|
Baseline to 3-month post treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 10, 2023
Primary Completion (Estimated)
September 30, 2024
Study Completion (Estimated)
June 30, 2027
Study Registration Dates
First Submitted
March 29, 2022
First Submitted That Met QC Criteria
March 29, 2022
First Posted (Actual)
April 6, 2022
Study Record Updates
Last Update Posted (Actual)
March 22, 2024
Last Update Submitted That Met QC Criteria
March 21, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- S2473
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Varicose Veins
-
EMSWithdrawn
-
EMSWithdrawn
-
I-VASC S.r.lRecruiting
-
Acotec Scientific Co., LtdZhejiang UniversityCompletedVaricose Veins of Lower LimbChina
-
Beijing Tsinghua Chang Gung HospitalActive, not recruiting
-
Oulu University HospitalCompletedVaricose Veins | Varicose Veins of Lower LimbFinland
-
Kahramanmaras Sutcu Imam UniversityUnknown
-
Helsinki University Central HospitalActive, not recruiting
-
The Fourth Affiliated Hospital of Zhejiang University...RecruitingVaricose Veins of Lower LimbChina
-
Worcestershire Acute Hospitals NHS TrustCompletedVaricose Veins of Lower LimbUnited Kingdom
Clinical Trials on Varithena®
-
Boston Scientific CorporationCompletedVenous Leg UlcerUnited States, Canada
-
Boston Scientific CorporationCompletedVaricose VeinsUnited States
-
OhioHealthBTG International Inc.WithdrawnLeg Ulcer | Varicose Veins | Varicose Ulcer | Venous Leg Ulcer | Venous Reflux | Reflux | Venous Ulcer | Veins, Varicose | Varicose Veins LegUnited States
-
UPECLIN HC FM Botucatu UnespFundação de Amparo à Pesquisa do Estado de São PauloCompletedVaricose Veins | TelangiectasisBrazil
-
UPECLIN HC FM Botucatu UnespFundação de Amparo à Pesquisa do Estado de São PauloCompleted
-
ProMedica Health SystemJobst Vascular InstituteRecruitingVenous Insufficiency | Venous Reflux | Venous Ulcer | Venous DiseaseUnited States
-
Dong-A ST Co., Ltd.CompletedFunctional DyspepsiaKorea, Republic of
-
Galderma R&DCompletedAtopic DermatitisPhilippines, China
-
Chong Kun Dang PharmaceuticalCompleted
-
Amir AzarpazhoohInstitut Straumann AGCompletedPeriodontal Inflammation | Crown LengtheningCanada